Szemészet, 2013 (150. évfolyam, 1-4. szám)

2013-03-01 / 1. szám

Amit ma tudunk az időskori macula degenerációról

Irodalom

1. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulaton-induced regression. Major review. Surv Ophthalmol 1999; 44: 1-29.

2. Age-Related Eye Disease Study Research Group. A randomised, placebo-controlled clinical trial of high-dose supplementation with vitamin C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. Arch Ophthalmol 2001; 119: 1417-36.

3. Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. AREDS report number 22. Arch Ophthalmol 2007; 125: 1225-32.

4. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.

5. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv of Ophthalmology 2003; 48: 257-293.

6. American Academy of Ophthalmology: Age-related macular degeneration, Preferred practice pattern, www.http://www.aao.org/ppp. 2008.

7. Bird AC, Bressler NM, Bressler SB, et al. International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39: 367-74.

8. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from agerelated macular degeneration in Denmark: year 2000-2010. Am J Ophthalmol 2012; 153: 209-213.

9. Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2,0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary endpoint. Ophthalmol 2012; nov 3. pii: S0161—6420 (12) 00763-4.

10. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.

11. Chaine G, Hullo A, Sahel J, et al. For the France-DMLA Study Group. Case-control study of the risk factors for age-related macular degeneration. Br J Ophthalmol 1998; 82: 996-1002.

12. Chakravarthy U, Harding SR Rogers CA, et al. The IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovacular age-related macular degeneration. Ophthalmol 2012; 119: 1399-1411.

13. Chen H, Liu K, Chen LJ, et al. Genetic associations in polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Molecular Vision 2012; 18: 816-829.

14. Chiang A, Chang LK, Yu E Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008; 28: 1265-69.

15. Cho E, Hankinson SE, Rosner B, et al. Prospective study of lutein/zeaxantin intake and risk of age-related macular degeneration. Am J Clin Nutr 2008; 87: 1837-43.

16. Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary omega-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol 2011; 129: 921-29.

17. Coscas G. Clinical analysis and interpretation of OCT characteristics in AMD. Clinical features and natural history of AMD on OCT. Comparison with angiography. In: Coscas G, Coscas E Vismara S, et al.

editors. Optical Coherence Tomography in age-related macular degeneration. 2nd ed. Springer-Verlag 2010; 99-169, 197-274.

18. Fehér J, Kovács В, Kovács I, et al. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with combination of Acetyl-L-Carnitine, n-3- fatty acids, and coenzyme Q10. Ophthalmologies 2005; 219: 154-166.

19. Grassmann E Fritsche LG, Keilhauer ON, et al. Modelling the genetic rise in age-related macular degeneration. PloS one 2012; 7: e37979.

20. Győry J. A szemfenéki kékeszöld autofluorescencia (488 nm) és az infravörös-közeli autofluorescencia (787 nm) szerepe különféle AMD- vel kapcsolatos RPE-elváltozások láthatóvá tételében. Absztrakt. Szemészet 2012; 149 (Suppl I): 52

21. Haan MN, Klein R, Klein BE, et al. Hormone therapy and age-related macular degeneration: The Women's Health Initiative Sight Exam Study. Arch Ophthalmol 2006; 124: 988-92.

22. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012 Oct 17. doi: pii: S0161-6420 (12) 00865-2. 10.1016/ j.ophtha.2012.09.006. (Epub ahead of print)

23. Imamura Y, Engelbert M, lida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010; 55: 501-515.

24. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. A report by the American Academy of Ophthalmology. Ophthalmol 2008; 115: 1837-46.

25. Jampol LM. Antioxidants, zinc and age-related macular degeneration. Results and recommendations. Editorial. Arch Ophthalmol 2001; 119: 1533-1534.

26. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and metaanalysis. Ophthalmology 2010; 117: 921-7.

27. Kellner (J, Kellner S, Weinitz S. Fundus autofluorescence (488 nm) and near-infrared autofluorescence (787 nm) visualize different retinal pigment epithelium alterations in patients with age-related macular degeneration. Retina 2010; 30: 6-15.

28. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age-related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006; 90: 75-80.

29. Kinnunen K, Petrovski G, Мое MC, et al. Molekular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 2012; 90: 299-309.

30. Klein R, Klein BEK, Linton KLP Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-943.

31. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of agerelated macular degeneration and associated risk factors: The Beaver Dam Offspring Study. Arch Ophthalmol 2010; 128: 750-758.

32. Klein R, Chou C-E Klein BEK, et al. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011; 129: 75-80.

33. Kölkedi Zs, Tóth-Kovács К, Pámer Zs. Életminőség változása VEGF- gátlóval kezelt időskori macula degenerációban szenvedő betegeknél. Szemészet 2011; 147: 133-137.

34. Kurihara T, Ozawa Y, Ishida S, et al. Renin-angiotensin system hyperactivation can include inflammation and retinal neuron dysfunction. Int J Inflam 2012; ID: 581695.

35. Leveziel N, Tilleul J, Puche N, et al. Genetic factors associated with age-related macular degeneration. Ophthalmologies 2011; 226: 87-102.

36. Losonczy G, Fekete A, Vokó Z, et al. Analyis of complement factor H